Skip to content

Don't Go There: A Geospatial mHealth App for Gambling Disorder

Don't Go There: A Geospatial mHealth App for Gambling Disorder

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04158037
Enrollment
0
Registered
2019-11-08
Start date
2024-07-31
Completion date
2025-06-01
Last updated
2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gambling Disorder

Keywords

mHealth App

Brief summary

The goal of this project is to develop and to test the efficacy of a novel mHealth app for gambling disorder. The app capitalizes on smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. Users will receive an alert of this go near a gambling venue. The project will conduct a 12-week pilot randomized clinical trial to test the short-term efficacy of the app with gambling disorder individuals.

Interventions

BEHAVIORALmHealth App

The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.

Sponsors

National Center for Responsible Gaming
CollaboratorOTHER
St. Louis University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Currently meets DSM-5 criteria for gambling disorder * At least 4 non-online gambling episodes in past 60 days * Wagering at least $100 total over past 60 days * Willingness to accept random assignment * English speaking * Android phone user

Exclusion criteria

* Age \<18 years old * Severely disruptive behavior * Serious uncontrolled psychiatric behavior that requires acute psychiatric care * Decline permission to collect zero permission data from smartphone.

Design outcomes

Primary

MeasureTime frameDescription
App usage (feasibility)From baseline to post-treatment (12 weeks)Number of days the app is active on a user's smartphone. Days can range from 0 to 84.
Patient satisfaction with the gambling appFrom baseline to post-treatment (12 weeks)Investigator derived patient satisfaction self-report questionnaire. Five items, using a 7-point Likert scale from very dissatisfied (1) to very satisfied (7). Higher scores indicate a better outcome.

Secondary

MeasureTime frameDescription
Gambling behavior via Timeline Followback (Weinstock, Whelan, & Meyers, 2004)From baseline to post-treatment (12 weeks)Self-report gambling frequency and intensity as assessed by the Gambling Timeline Followback - a retrospective self-report calendar. Gambling frequency can range from 0 to 84; gambling intensity is measured in $ and time (hours). Dollars wagered can range from $0 to unlimited $. Time is measured in hours and can range from 0 to \>1,000 hours. Higher scores indicate a worse outcome.
Gambling-related harms (Browne et al., 2018)From baseline to post-treatment (12 weeks)Self-reported gambling harms as assessed by the 72-item Gambling-Related Harms Questionnaire (yes/no responses). Scores range from 0 to 72. Higher scores indicate a worse outcome.
Quality of Life Inventory (Frisch et al., 1994). A self-reported quality of life measure assessing 17 domains of life for importance and satisfaction.From baseline to post-treatment (12 weeks)Self-report quality of life questionnaire. Participants rate 17 domains on importance (range not at all important \[0\] to extremely important \[2\]). The 17 domains are then rated on how satisfied the individual is regards to his or her life (-3 \[very dissatisfied\] to 3 \[very dissatisfied\]). A total score is then generated by summing the product of importance multiplied by satisfaction. Scores range from 0 to 102. Higher scores indicate a better outcome.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026